Product name:SR9009
CAS:1379686-30-2
Appearance:Light yellow powder
Assay: 99%
Chemicalname:Ethyl-3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylate
Description
SR9009, which is currently under development at The Scripps
Research Institute (TSRI), increases the level of metabolic
activity in skeletal muscles of mice. Treated mice become lean,
develop larger muscles and can run much longer distances simply by
taking SR9009, which mimics the effects of aerobic exercise. If
similar effects can be obtained in people, the reversal of obesity,
metabolic syndrome, and perhaps Type-II diabetes might be the very
welcome result.
The drug was developed by Professor Thomas Burris, who found that
it was able to reduce obesity in populations of mice. It binds to
and activates a protein called Rev-ErbAα, which influences fat and
sugar burning in the liver, production of fat cells, and the body's
inflammatory response.
Reference
If the effects of SR9009 on mice can safely be reproduced for
people, the new drug may offer new therapies for obesity and its
companions, metabolic syndrome and diabetes. Another area in which
SR9009 or a similar drug may confer substantial benefit is to
offset the loss of general muscle conditioning which occurs as a
side effect of reduced activity caused by illness and/or aging.
People most likely to enjoy these benefits include those suffering
from severe arthritis, congestive heart failure, chronic
obstructive pulmonary disease (COPD), and other conditions that
restrict the ability to exercise.